Women with rheumatoid arthritis have to be cautious while opting for parenthood. By addressing the issue at the earliest ...

Arthritis affects millions worldwide, causing pain and reduced mobility. Adopting an anti-inflammatory diet can help manage ...

On World Arthritis Day 2024, we shine a spotlight on the importance of making informed choices for better health outcomes in ...

Rheumatoid arthritis (RA) is associated with higher health care expenditures and suboptimal quality of life in U.S. adults, ...

Discover the crucial connection between body weight and arthritis. Learn how excess weight accelerates joint degeneration, ...

Are you struggling with joint pain or stiffness? Arthritis can make even the simplest daily tasks, like walking or opening ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Delay in proper knee treatment, timely detection and ignoring knee arthritis symptoms can worsen the condition of knees and ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Frank D. Heuszel, CEO of Impact BioMedical, commented, "The Canadian Inflammatory Disease Treatment Market was estimated to be 7B in 2022 according to Precedence research. This patent issuance ...